June 14, 2024

What is BioConvergence?

Explor Space and US-Based BioGravity LLC Announce BioCovergence:

Next generation healthcare solutions aren’t just inspired by nature. They actively incorporate biological systems and processes, unlocking possibilities that were unthinkable just a few years ago. But what is this paradigm shift? What exactly is bioconvergence? And what does it mean for the future of healthcare?

3D BioPrinting Meets Simulated Microgravity on the BioGravity Platforms

AKA Lab on Chip

The Explor Space mechanobiology platform allows clients to study
the bioconvergence between microfluidics, 3D bioprinting, lab-on-chip and microgravity technologies.

This new approach innovates on biological microenvironments including brain cancer. This emergence of space mechanobiology on-earth has demonstrated potential to unveiling biological mechanisms and disease function regardless of ISS functioning.

Mated with the simulated microgravity BioGravity™ platform, your team can speed advances in bioinformatics, proteins, ecoli, industrial applications, and even single particle grids for around $50K annually.

One example of BioConvergence can be seen in brain tumors.

Glioblastoma multiforme (GBM) is one of the most aggressive malignant brain tumors and urgently requires the development of new therapeutic strategies. In this study, an innovative hybrid in vitro vascularized GBM-on-a-chip model is presented as a strategic integration of microfluidics and 3D bioprinting technologies. The system can recreate the compartmentalized brain tumor microenvironment, comprising the functional blood brain barrier (BBB) and the adjacent 3D perivascular tumor niche, by selectively mimicking physiological shear stress and cell–cell, cell–matrix mechanical interaction. The GBM-on-a-chip model was evaluated under simulated microgravity (µG) condition as a form of mechanical unloading showing a significant cell morphological and mechanotransduction response thereby indicating that gravitational forces play an important role in glioblastoma mechanical regulation. The proposed GBM-on-a-chip represents a meaningful biological tool for further research in cancer mechanobiology and pre-clinical approach in brain tumor therapy.


For consultation on your BioConvergence project, contact Frank Pournelle @ BioGravity LLC by calling 800-334-4500